The LUX-Lung 3 and LUX-Lung 6 clinical trials compared afatinib with cisplatin-based doublet chemotherapy in advanced NSCLC patients with EGFR mutation [39, 40]. Here, EGFR is linked to non-small cell lung carcinoma.